Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Based on Phase 3 trial completion timelines, analysts project an NDA submission in late 2026 or early 2027, with FDA review taking approximately 12 months
Patients initiating semaglutide therapy should anticipate gradual changes in appetite and eating patterns, typically beginning within the first two to four weeks of treatment
In trial 4, 5.8 % of Semaglutide treated patients discontinued, and 11.6 % of placebo-treated patients ceased the prosecution
Liraglutide becoming generic may make it easier to get and less expensive
US$ 23.87
US$ 20.80
US$ 24.26
US$ 21.02
US$ 22.47
US$ 21.75
